CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
002898 Sailong Pharmaceutical Group
- 6.26
- +0.29+4.86%
Market Closed Apr 30 15:00 CST
1.10BMarket Cap-30.84P/E (TTM)
6.27High5.93Low99.44KlotVolume5.93Open5.97Pre Close61.04MTurnover9.82%Turnover RatioLossP/E (Static)176.00MShares12.3952wk High2.21P/B633.90MFloat Cap5.7752wk Low6.27Limit Up101.26MShs Float30.73Historical High5.67Limit Down5.70%Amplitude5.77Historical Low0.02Dividend TTM6.14Avg Price48.55KlotAsk0.32%Div YieldTTM100Lot Size50.03KlotBid
Sailong Pharmaceutical Group News
Sailong Pharmaceutical Group (002898.SZ): Net loss of 1.0385 million yuan in the first quarter.
Gelonghui, April 25th丨Sailong Pharmaceutical Group (002898.SZ) announced the Q1 report for 2025, with revenue of 54.0868 million yuan, a year-on-year decrease of 22.16%; Net income attributable to shareholders of the listed company was -1.0385 million yuan; Net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -1.1062 million yuan; Basic EPS was -0.0059 yuan.
Cailong Pharmaceuticals: First Quarter Report 2025
Cailong Pharmaceuticals: 2024 Annual Report Summary
Cailong Pharmaceuticals: 2024 Annual Report
Sailong Pharmaceutical Group (002898.SZ): Currently, no antiviral drugs specifically targeting norovirus are being produced.
Gelonghui April 22丨Sailong Pharmaceutical Group (002898.SZ) stated on the interactive platform that the company is currently not producing antiviral drugs specifically targeting norovirus.
Sailong Pharmaceutical Group (002898.SZ): The company currently has no export business.
Gelonghui April 16丨Sailong Pharmaceutical Group (002898.SZ) stated on the interactive platform that the company has no export business for the time being, and specific situations can be monitored through the company's regular reports.
Risks Still Elevated At These Prices As Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) Shares Dive 31%
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Cailong Pharmaceutical: 2024 Annual Results Forecast Revision Announcement
Sailong Pharmaceutical Group (002898.SZ): Voriconazole has received the approval notification for the listing application of Chemical Raw Materials.
Gelonghui, February 20, Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the approval notification for the listing application of Voriconazole as a Chemical Raw Material from the National Medical Products Administration. Voriconazole formulation is a broad-spectrum triazole antifungal agent primarily used to treat the following fungal infections: (1) Invasive aspergillosis. (2) Candidemia in patients with neutropenia. (3) Serious invasive infections caused by Candida species resistant to fluconazole (including Candida krusei). (4) Severe infections caused by the genera Scedosporium and Fusarium.
Cailong Pharmaceuticals: 2024 Annual Results Forecast
Sailong Pharmaceutical Group (002898.SZ): Net income for the 2024 fiscal year is expected to decline by 31.82% to 52.80%.
On January 21, Gelonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced its performance forecast for 2024, estimating a net income attributable to shareholders of the listed company of 4.5 million yuan to 6.5 million yuan, a decrease of 31.82% to 52.80% compared to the same period last year; the net income after deducting non-recurring gains and losses is expected to be 4.2 million yuan to 6.2 million yuan; the basic EPS is expected to be 0.0256 yuan/share to 0.0369 yuan/share. In 2024, the company's net income attributable to shareholders of the listed company is expected to decline year-on-year, mainly due to a decrease of approximately 11.65 million yuan in non-recurring gains and losses compared to the same period last year.
Sailong Pharmaceutical Group (002898.SZ): Received the approval notice for the listing application of the Chemical Raw Materials Active Pharmaceutical Ingredient famotidine.
On January 1st, Gelonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the "Approval Notice for the Marketing Application of Chemical Raw Materials for Famotidine" issued by the National Medical Products Administration. Famotidine formulation is mainly used to treat upper gastrointestinal bleeding caused by digestive ulcers, as well as mucosal erosion and bleeding of the stomach and duodenum due to various causes other than tumors and esophageal or gastric varices.
Sailong Pharmaceutical Group (002898.SZ): Participating in the tenth batch of national Pharmaceutical centralized procurement, expected to win the bid.
On December 13, Glonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical (Changsha) Co., Ltd. (hereinafter referred to as "Changsha Sailong") participated in the bidding work organized by the Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") for the tenth batch of national centralized procurement of pharmaceuticals. Some of the company's products are expected to win bids in this centralized procurement.
Sailong Pharmaceutical Group (002898.SZ) has obtained the supplementary approval letter for Pregabalin Capsules.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently received...
Sailong Pharmaceutical Group (002898.SZ): Sailong Polaris has cumulatively reduced its shareholding by 1%.
On November 4th, Geronghui reported that Sailong Pharmaceutical Group (002898.SZ) recently received a notification letter from shareholder Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd., holding more than 5% of the shares, about the change in equity reaching 1%. It was learned that following the company's previous disclosure of the announcement of shareholders reducing their holdings by more than 1%, Sailong Juzhi reduced the company's shares by 130,000 shares through centralized auction trading from November 26, 2022, to November 28, 2022, between May 4, 2023, and June 2, 2023, through centralized auction trading.
Cailong Pharmaceuticals: Report for the third quarter of 2024
Sailong Pharmaceutical Gets Approval Notice for Fluorouracil Listing
Sailong Pharmaceutical Group (002898.SZ): Subsidiary has obtained the approval notice for the application for listing of chemical raw materials.
On September 25th, Gelonhui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently obtained the National Medical Products Administration's approval and issuance of the approval notice for the listing application of hydrochloride esmolol as an active pharmaceutical ingredient. The main indications for hydrochloride esmolol preparations are: used to treat paroxysmal supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension.